Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics is a biotechnology company focused on developing targeted therapies for genetically defined tumors. Their pipeline includes innovative inhibitors designed to address oncogenic mutations in EGFR and BRAF.
Company Overview
Black Diamond Therapeutics pioneers targeted cancer therapies, leveraging its Mutation-Allostery-Pharmacology (MAP) platform to develop innovative inhibitors like BDTX-189 and BDTX-1535, addressing unmet needs in genetically defined tumors and positioning the company for significant growth in the biotechnology sector.
Investment Thesis
Black Diamond Therapeutics presents a compelling investment opportunity due to its innovative MAP platform and promising pipeline of targeted cancer therapies. The company's lead candidate, BDTX-189, targets a significant unmet need in patients with non-canonical EGFR and HER2 mutations. Furthermore, the development of BDTX-1535, a brain-penetrant EGFR inhibitor, addresses the challenge of brain metastases, a common complication in cancer patients. The company's high gross margin of 99.9% suggests strong pricing power and efficient operations. With a market capitalization of $0.13 billion and a P/E ratio of 5.94, BDTX may be undervalued relative to its growth potential. Upcoming clinical trial data for BDTX-189 and BDTX-1535 could serve as major catalysts, driving investor interest and stock appreciation. The strategic partnership with OpenEye Scientific Software further strengthens Black Diamond's drug discovery capabilities.
Key Highlights
- Market Cap of $0.13 billion indicates the company's current valuation in the market.
- P/E ratio of 5.94 suggests the company may be undervalued compared to its earnings.
- Profit Margin of 30.7% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 99.9% highlights the company's efficient cost management and pricing strategy.
- Beta of 3.36 indicates the stock's high volatility relative to the market.
Competitors
Strengths
- Proprietary MAP platform for targeted drug discovery.
- Pipeline of innovative inhibitors targeting specific cancer mutations.
- Brain-penetrant inhibitor technology addressing brain metastases.
- Strategic partnership with OpenEye Scientific Software.
Weaknesses
- Limited number of employees (24) may constrain operational capacity.
- Reliance on clinical trial success for drug development.
- High beta (3.36) indicates high stock volatility.
- Early-stage biotechnology company with no currently marketed products.
Catalysts
- Upcoming: Clinical trial data releases for BDTX-189 in non-canonical EGFR/HER2 mutated cancers.
- Upcoming: Clinical trial data releases for BDTX-1535 in EGFR-mutated cancers with brain metastases.
- Ongoing: Advancement of BDTX-4933 into clinical development for BRAF-altered cancers.
- Ongoing: Potential for strategic partnerships and collaborations to accelerate drug development.
- Ongoing: Expansion of the MAP platform to identify new drug targets.
Risks
- Potential: Clinical trial failures or delays in drug development.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Potential: Regulatory hurdles and delays in drug approvals.
- Ongoing: High beta (3.36) indicates high stock volatility.
- Ongoing: Dependence on securing additional funding for research and development.
Growth Opportunities
- Expansion of BDTX-189 Development: BDTX-189 targets non-canonical EGFR and HER2 mutations, representing a significant market opportunity in lung cancer and other solid tumors. The company can expand the development of BDTX-189 to include additional indications and combination therapies. The market for EGFR inhibitors is projected to reach billions of dollars, offering substantial revenue potential for Black Diamond. Successful clinical trials and regulatory approvals could drive significant growth in the coming years.
- Advancement of BDTX-1535 Program: BDTX-1535, a brain-penetrant EGFR inhibitor, addresses a critical unmet need in patients with brain metastases. The company can accelerate the development of BDTX-1535 and explore its potential in various EGFR-mutated cancers. The market for brain-penetrant cancer therapies is growing, driven by the increasing incidence of brain metastases. Positive clinical data and regulatory approvals could establish BDTX-1535 as a leading treatment option.
- Development of BDTX-4933: BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF alterations, targets a different set of genetically defined tumors. The company can advance the development of BDTX-4933 and explore its potential in BRAF-mutated cancers. The market for BRAF inhibitors is expanding, driven by the increasing understanding of BRAF mutations in various cancers. Successful clinical trials and regulatory approvals could create another significant revenue stream for Black Diamond.
- Strategic Partnerships and Collaborations: Black Diamond can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its pipeline. Collaborations can provide access to additional resources, expertise, and funding. The company's existing partnership with OpenEye Scientific Software demonstrates its commitment to collaboration. Expanding its network of partners could enhance Black Diamond's growth prospects.
- Expansion of MAP Platform Applications: Black Diamond's Mutation-Allostery-Pharmacology (MAP) platform can be leveraged to discover and develop additional targeted therapies for genetically defined tumors. The company can expand the application of its MAP platform to identify new drug targets and develop novel inhibitors. The platform's ability to identify allosteric mechanisms of cancer-causing mutations provides a competitive advantage. Expanding the platform's applications could lead to the discovery of new blockbuster drugs.
Opportunities
- Expansion of MAP platform applications to new drug targets.
- Strategic collaborations with pharmaceutical companies.
- Positive clinical trial results driving stock appreciation.
- Regulatory approvals leading to commercialization of drug candidates.
Threats
- Clinical trial failures leading to pipeline setbacks.
- Competition from other biotechnology and pharmaceutical companies.
- Regulatory hurdles and delays in drug approvals.
- Market volatility and economic downturn affecting funding and valuation.
Competitive Advantages
- Proprietary Mutation-Allostery-Pharmacology (MAP) platform for drug discovery.
- Strong intellectual property portfolio protecting its drug candidates and platform technology.
- Expertise in targeting allosteric mechanisms of cancer-causing mutations.
- Brain-penetrant inhibitor technology addressing brain metastases.
About
Black Diamond Therapeutics, Inc., founded in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company dedicated to discovering and developing innovative medicines for patients with genetically defined tumors. Originally named ASET Therapeutics, Inc., the company rebranded in January 2018 to reflect its focus on targeting the allosteric mechanisms of cancer-causing mutations. Black Diamond's core technology is its Mutation-Allostery-Pharmacology (MAP) platform, which enables the company to identify and develop small molecule inhibitors that selectively target oncogenic proteins. The company's lead product candidate, BDTX-189, is an irreversible small molecule inhibitor designed to target non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. BDTX-1535, another key asset, is a brain-penetrant inhibitor targeting EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations. Additionally, the company is developing BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II, and III alterations. Black Diamond has a strategic partnership with OpenEye Scientific Software, Inc., enhancing its drug discovery capabilities. With a focused pipeline and a proprietary technology platform, Black Diamond Therapeutics aims to address significant unmet needs in cancer treatment by developing targeted therapies for patients with genetically defined tumors.
What They Do
- Discovers and develops medicines for patients with genetically defined tumors.
- Utilizes its Mutation-Allostery-Pharmacology (MAP) platform to identify and target oncogenic proteins.
- Develops irreversible small molecule inhibitors for specific cancer mutations.
- Creates brain-penetrant inhibitors to address brain metastases.
- Focuses on epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations.
- Develops inhibitors of oncogenic BRAF class I, II and III alterations.
Business Model
- Develops and patents novel targeted cancer therapies.
- Out-licenses or co-develops its drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments and royalties on partnered drugs.
- Potentially commercializes its own drugs upon regulatory approval.
Industry Context
Black Diamond Therapeutics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for targeted cancer therapies is experiencing substantial growth, driven by advances in genomics and personalized medicine. Companies like Black Diamond are positioned to capitalize on this trend by developing drugs that address specific genetic mutations in tumors. The competitive landscape includes companies such as AVTX, CRBU, and ENTA, which are also developing novel cancer therapies. The biotechnology industry is expected to continue growing, fueled by increasing demand for innovative treatments and advancements in drug discovery technologies.
Key Customers
- Patients with genetically defined tumors, including lung cancer and other solid tumors.
- Oncologists and other healthcare professionals who treat cancer patients.
- Pharmaceutical companies seeking to in-license or co-develop novel cancer therapies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $70M | $57M | $0.98 |
Source: Company filings
Chart & Info
Price Chart
Black Diamond Therapeutics, Inc. (BDTX) stock price: $2.23 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in the company's long-term potential, indicating that key stakeholders believe in its future success.
- •Community sentiment has shifted positively, with discussions highlighting optimism around ongoing clinical trials and their potential impact on the market.
- •The company has made significant strides in its research pipeline, which has garnered attention and support from biotech enthusiasts and investors alike.
- •Black Diamond's innovative approach to targeted therapies resonates with a growing trend towards precision medicine, attracting interest from both retail and institutional investors.
Why Bear
- •Concerns have been raised regarding the pace of clinical trial results, leading to skepticism about the company's ability to deliver on its promises in a timely manner.
- •Social sentiment has shown a mix of caution, with some community members expressing doubts about the sustainability of recent gains amidst regulatory uncertainties.
- •Recent market developments have led to increased competition in the biotech space, putting pressure on Black Diamond to differentiate itself effectively.
- •The overall volatility in the biotech sector has made some investors wary, leading to a more bearish outlook among those who prioritize stability over potential high rewards.
Latest News
-
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
Insider Monkey · Feb 2, 2026
-
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
Yahoo! Finance: BDTX News · Feb 2, 2026
-
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Yahoo! Finance: BDTX News · Jan 28, 2026
-
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Business Wire · Jan 28, 2026
Technical Analysis
Rationale
AI-generated technical analysis for BDTX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Black Diamond Therapeutics, Inc. (BDTX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for BDTX.
Make a Prediction
Set your price target for Black Diamond Therapeutics, Inc. (BDTX), choose a timeframe, and track your prediction accuracy.
Current price: $2.23
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDTX.
Price Targets
Median: $8.00 (+258.7% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 10/100
Gross margin of 99.9% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Limited cash of $36M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 1.47% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates BDTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer
Frequently Asked Questions
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics is a biotechnology company focused on discovering, developing, and commercializing targeted therapies for patients with genetically defined tumors. The company's core technology is its Mutation-Allostery-Pharmacology (MAP) platform, which enables the identification and development of small molecule inhibitors that selectively target oncogenic proteins. Their pipeline includes BDTX-189, an irreversible small molecule inhibitor targeting non-canonical EGFR and HER2 mutations, and BDTX-1535, a brain-penetrant inhibitor targeting EGFR mutations, including those resistant to existing therapies. Black Diamond aims to address unmet needs in cancer treatment by developing precision medicines for specific genetic mutations.
Is BDTX stock a good buy?
BDTX stock presents a speculative investment opportunity with potential for high returns, but also significant risks. The company's innovative MAP platform and promising pipeline of targeted cancer therapies offer compelling growth prospects. However, the company is still in the early stages of clinical development, and clinical trial failures could negatively impact the stock price. The high beta of 3.36 indicates high stock volatility. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in BDTX stock. Upcoming clinical trial data will be critical in determining the company's future prospects.
What are the main risks for BDTX?
The main risks for Black Diamond Therapeutics include clinical trial failures, competition from other biotechnology and pharmaceutical companies, regulatory hurdles and delays in drug approvals, high stock volatility, and dependence on securing additional funding for research and development. Clinical trial failures could significantly impact the company's pipeline and valuation. Competition from larger, more established companies could limit Black Diamond's market share. Regulatory delays could delay the commercialization of its drug candidates. The company's high beta indicates that its stock price is more volatile than the overall market. Securing additional funding may be challenging in a volatile market environment.
Is BDTX a good stock to buy?
Whether BDTX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the BDTX MoonshotScore?
The MoonshotScore for BDTX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is BDTX data updated?
BDTX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BDTX is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for BDTX?
Growth catalysts for Black Diamond Therapeutics, Inc. (BDTX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Black Diamond Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are BDTX's main competitors?
Black Diamond Therapeutics, Inc. (BDTX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BDTX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about BDTX?
Wall Street analyst coverage for BDTX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is BDTX's market cap?
Market capitalization (market cap) for BDTX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BDTX's current market cap alongside enterprise value and other valuation metrics.
How has BDTX stock performed recently?
BDTX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BDTX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in BDTX?
Key risk categories for BDTX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BDTX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling BDTX?
Insider trading activity for BDTX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is BDTX a good stock for beginners?
Black Diamond Therapeutics, Inc. (BDTX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is BDTX for first-time investors?
Every stock carries risk, including Black Diamond Therapeutics, Inc. (BDTX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BDTX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Stock data pending update.